Gut microbiome in hemodialysis patients treated with calcium acetate or treated with sucroferric oxyhydroxide : a pilot study
Merino Ribas, Ana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Araujo, Ricardo (Universidade Do Porto)
Bancu, Ioana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Graterol, Fredzzia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Vergara, Andrea (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Noguera-Julian, Marc (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Paredes, Roger (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Bonal, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Sampaio-Maia, Benedita (University of Porto)
Universitat Autònoma de Barcelona

Date:	2021
Abstract:	It has been proved that the gut microbiome is altered in patients with chronic kidney disease. This contributes to chronic inflammation and increases cardiovascular risk and mortality, especially in those undergoing hemodialysis. Phosphate binders may potentially induce changes in their microbiome. This trial aimed to compare the changes in the gut microbiome of hemodialysis patients treated with calcium acetate to those treated with sucroferric oxyhydroxide. Twelve hemodialysis patients were distributed to receive calcium acetate or sucroferric oxyhydroxide for 5 months. Blood samples (for biochemical analysis) and stool samples (for microbiome analysis) were collected at baseline, 4, 12, and 20 weeks after treatment initiation. Fecal DNA was extracted and a 16S rRNA sequencing library was constructed targeting the V3 and V4 hypervariable regions. Regarding clinical variables and laboratory parameters, no statistically significant differences were observed between calcium acetate or sucroferric oxyhydroxide groups. When analyzing stool samples, we found that all patients were different (p = 0. 001) among themselves and these differences were kept along the 20 weeks of treatment. The clustering analysis in microbial profiles grouped the samples of the same patient independently of the treatment followed and the stage of the treatment. These results suggest that a 5-month treatment with either calcium acetate or sucroferric oxyhydroxide did not modify baseline diversity or baseline bacterial composition in hemodialysis patients, also about the high-variability profiles of the gut microbiome found among these patients.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Calcium acetate ; Chronic kidney disease ; Gut microbiome ; Hemodialysis ; Phosphate binders ; Sucroferric oxyhydroxide
Published in:	International Urology and Nephrology, Vol. 54 (december 2021) , p. 2015-2023, ISSN 1573-2584

DOI: 10.1007/s11255-021-03091-3
PMID: 34923600

9 p, 1.3 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles